Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Chubb
AstraZeneca
Healthtrust
Citi
Boehringer Ingelheim
Cerilliant
Baxter
Merck

Generated: December 12, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ERYC SPRINKLES

« Back to Dashboard

Clinical Trials for Eryc Sprinkles

Trial ID Title Status Sponsor Phase Summary
NCT00136266 Adherence With Iron Sprinkles Among High-Risk Infants Completed Centers for Disease Control and Prevention Phase 3 Compared with iron drops, iron sprinkles supplied for 3 months to high-risk children beginning at age 5-7 months will increase adherence and reduce the rates of anemia and iron deficiency.
NCT00210574 A Pilot Study of Topiramate in Childhood Absence Epilepsy Completed Ortho-McNeil Neurologics, Inc. Phase 2 Limited data exist on the effectiveness of antiepileptic drugs for treatment of childhood absence epilepsy. Preliminary data suggest that topiramate may be an effective drug for this condition. The present study is designed to provide further evidence of the potential effectiveness of topiramate for childhood absence epilepsy, as well as preliminary information about a potential target dose for future study.
NCT00210574 A Pilot Study of Topiramate in Childhood Absence Epilepsy Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 2 Limited data exist on the effectiveness of antiepileptic drugs for treatment of childhood absence epilepsy. Preliminary data suggest that topiramate may be an effective drug for this condition. The present study is designed to provide further evidence of the potential effectiveness of topiramate for childhood absence epilepsy, as well as preliminary information about a potential target dose for future study.
NCT00213161 Using Iron Supplementation to Decrease Iron Deficiency Anemia in Infants and Young Children in India Completed The Hospital for Sick Children N/A The purpose of this study is to determine the smallest dose of Sprinkles, a single-serving package of iron and other micronutrients, to treat infants with iron deficiency anemia in India. Results have implications for programs using Sprinkles worldwide because lower doses of iron may have fewer side effects.
NCT00233012 A Study of the Pharmacokinetics, Safety and Tolerability of Topiramate in Infants (Age 1-24 Months) With Refractory Partial-onset Seizures Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 1 The purpose of this study is to evaluate the pharmacokinetics safety and tolerability of topiramate in infants aged 1-24 months with refractory partial-onset seizures. Topiramate is an antiepileptic drug approved for use in adult and pediatric patients (aged 2 to 16 years) with refractory partial onset seizures (POS) with or without secondarily generalized seizures, primary generalized tonic clonic seizures, or Lennox-Gastaut syndrome (LGS).
NCT00379158 Comparison of the Efficacy and Acceptability of Three Types of Micronutrient Supplements in Ghana Completed Nestlé Foundation Phase 4 1. At 12 mo of age, all three intervention groups will have significantly better iron and vitamin A status than the NI group. 2. Infants who receive the Foodlet or Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin B6, riboflavin and zinc status at 12 mo of age than the infants who receive the sprinkles containing iron and vitamin A only. 3. Infants who receive Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin A and essential fatty acid (linoleic, alpha-linolenic and docosahexaenoic, DHA) status at 12 mo of age than the infants who receive the Foodlet or sprinkles.
NCT00379158 Comparison of the Efficacy and Acceptability of Three Types of Micronutrient Supplements in Ghana Completed United States Agency for International Development (USAID) Phase 4 1. At 12 mo of age, all three intervention groups will have significantly better iron and vitamin A status than the NI group. 2. Infants who receive the Foodlet or Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin B6, riboflavin and zinc status at 12 mo of age than the infants who receive the sprinkles containing iron and vitamin A only. 3. Infants who receive Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin A and essential fatty acid (linoleic, alpha-linolenic and docosahexaenoic, DHA) status at 12 mo of age than the infants who receive the Foodlet or sprinkles.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Eryc Sprinkles

Condition Name

Condition Name for Eryc Sprinkles
Intervention Trials
Anemia 3
Infection 1
Epilepsy, Absence 1
Seizures 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Eryc Sprinkles
Intervention Trials
Anemia, Iron-Deficiency 2
Adrenal Insufficiency 1
Malnutrition 1
Seizures 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Eryc Sprinkles

Trials by Country

Trials by Country for Eryc Sprinkles
Location Trials
United Kingdom 1
Bangladesh 1
India 1
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Eryc Sprinkles
Location Trials
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Eryc Sprinkles

Clinical Trial Phase

Clinical Trial Phase for Eryc Sprinkles
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Eryc Sprinkles
Clinical Trial Phase Trials
Completed 6
Recruiting 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Eryc Sprinkles

Sponsor Name

Sponsor Name for Eryc Sprinkles
Sponsor Trials
The Hospital for Sick Children 2
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2
Diurnal Limited 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Eryc Sprinkles
Sponsor Trials
Other 15
Industry 5
U.S. Fed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Cipla
AstraZeneca
Express Scripts
McKesson
Medtronic
Fuji
Cantor Fitzgerald
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.